Center of Biomedical Research Excellence in Pathogen Host Interactions

病原体宿主相互作用生物医学卓越研究中心

• 批准号: 10261563
• 负责人: STEPHEN B PRUETT
• 金额: $ 214.49万
• 依托单位: MISSISSIPPI STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10261563
• 关键词: Address; Advisory Committees; American; Antibiotic Resistance; Antibiotics; Area; Award; Basic Science; Biological; Biomedical Research; Centers for Disease Control and Prevention (U.S.); Centers of Research Excellence; Characteristics; Collaborations; Communicable Diseases; Communities; Development; Equipment; Extramural Activities; Faculty; Foundations; Funding; Goals; Grant; Home; Investigation; Investments; Laboratories; Lead; Leadership; Mentors; Metabolic; Microbe; Microbial Biofilms; Mississippi; Phase; Pilot Projects; Productivity; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resistance; Role; Safety; Science; Scientist; Staphylococcus aureus; System; United States National Institutes of Health; Universities; Vaccines; Vector-transmitted infectious disease; Vendor; Veterinary Medicine; Virulence; Work; Writing; antimicrobial drug; cohesion; college; commercialization; field study; improved; interest; member; microbial; novel; pathogen; programs; recruit; square foot; synergism

Overall Abstract The Phase I COBRE at Mississippi State University (MSU) has catalyzed a transformation in the biomedical research enterprise, particularly in the research focus area of the COBRE, pathogen-host interactions. In the CVM Basic Sciences Department, where most COBRE investigators worked, the research culture has changed; 19 of 20 faculty members now have competitive extramural funding. Furthermore, the total NIH funding amount at Mississippi State University has increased from about $1.4 million in 2012 (just before the Phase I COBRE began) to about $5.4 million in 2016 (year 4 of the Phase I COBRE). Two of our Phase I investigators have graduated to independent status, and all have obtained significant levels of competitive extramural funding. In fact, these two independent Phase I investigators will serve on the Leadership Team in Phase II, which will continue relationships between Phase I and Phase II investigators to build functional teams that will be competitive for collaborative funding efforts. Continuing the transformation of biomedical research at MSU to yield a self-sustaining high level research enterprise is the goal of the Phase II COBRE described in this application. We have identified 5 excellent investigators (two of whom were hired during Phase I) to lead research projects in the Phase II COBRE. The projects include sufficient commonality to allow synergy, and all are novel and have the potential to open new avenues of investigation. For example, two projects focus on vector borne diseases, three projects investigate the role of microbial metabolic adaptations in virulence, and two projects involve Staphylococcus aureus. One of the most positive characteristics of our investigators is the spontaneous development of collaborations between Phase I and Phase II investigators, which has occurred even before the beginning of Phase II. Plans for Phase II take advantage of this by deliberately encouraging continued interactions between Phase I and Phase II investigators both in mentoring and in research collaboration. Each investigator in Phase II has identified a distinguished scientist who is a leader in his/her field of study to serve as an external mentor. Internal mentors (from MSU) will serve as advisors in both scientific areas and in grant writing. All members of the distinguished External Advisory Committee from Phase I have agreed to serve in the same role in Phase II. With funds from Phase I, physical facilities and research infrastructure have been substantially improved by purchase of major equipment, renovation of the HVAC system of 4 labs, and addition of 6 Biological Safety Cabinets. The support of MSU for research in pathogen-host interactions is also illustrated by the university’s substantial investment to acquire a BSL-3 modular lab (1200 square feet with 3 separate labs), which has been commissioned and should be operational by the summer of 2018. A major user will be one of our COBRE Phase I investigators. The proposed Phase II COBRE will allow initiatives begun in Phase I to continue and establish a critical mass of well-funded investigators who can conduct high impact research.

总体摘要 密西西比州立大学（MSU）的第一阶段COBRE已经催化了生物医学领域的转型。 研究企业，特别是在COBRE的研究重点领域，病原体-宿主相互作用。在 CVM基础科学部，大多数COBRE研究人员工作的地方，研究文化 改变; 19 20教员现在有竞争力的校外资金。此外，NIH 密西西比州立大学的资助金额从2012年的约140万美元（就在2012年之前） 第一阶段COBRE开始）到2016年（第一阶段COBRE的第4年）约为540万美元。我们的两个第一阶段 调查人员已逐步成为独立的地位，所有人都获得了相当高的竞争力， 校外资助事实上，这两名独立的第一阶段调查员将在领导小组中任职， 第二阶段，将继续第一阶段和第二阶段调查员之间的关系，以建立职能团队 这将是有竞争力的合作资金的努力。继续生物医学研究的转型 在密歇根州立大学，建立一个自我维持的高水平研究企业是COBRE第二阶段的目标， 这个应用程序。我们已经确定了5名优秀的调查员（其中两名是在第一阶段雇用的）， COBRE二期的研究项目。这些项目具有足够的共性，可以发挥协同作用， 是新颖的，并有可能开辟新的调查途径。例如，两个项目侧重于 媒介传播疾病，三个项目调查微生物代谢适应在毒力中的作用， 两个项目涉及金黄色葡萄球菌。我们调查人员最积极的特点之一是 I期和II期研究者之间自发开展合作， 甚至在第二阶段开始之前。第二阶段的计划利用了这一点， I期和II期研究者在指导和研究方面的持续互动 协作第二阶段的每一位研究者都确定了一位杰出的科学家，他/她是他/她所在领域的领导者。 研究领域，作为一个外部导师。内部导师（来自密歇根州立大学）将担任顾问， 科学领域和资助写作。尊敬的外部咨询委员会全体成员， 第一阶段已同意在第二阶段发挥同样的作用。利用第一阶段的资金， 通过购买主要设备、翻修 4个实验室的HVAC系统，并增加6个生物安全柜。MSU对研究的支持 该大学为获得BSL-3而进行的大量投资也说明了病原体-宿主相互作用 模块化实验室（1200平方英尺，有3个独立的实验室），已投入使用，应可运行 到2018年夏天。一个主要的用户将是我们的COBRE第一阶段调查员之一。拟议的第二阶段 COBRE将使第一阶段开始的倡议得以继续，并建立一个资金充足的关键质量 能够进行高影响力研究的调查人员。